Baxter
Executive Summary
Former Genetic Therapy and Systemix President & CEO Michael Perry, PhD, joins Baxter Oct. 4 as Hyland Immuno VP-global research & development. Baxter's vaccine business has been in a growth phase with the recent purchase of North American Vaccine and an equity investment in Peptide Therapeutics (1"The Pink Sheet" Sept. 25, p. 15)